Letters To The Editor Open Access
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 14, 2015; 21(34): 10054-10056
Published online Sep 14, 2015. doi: 10.3748/wjg.v21.i34.10054
PNPLA3 I148M variant affects non-alcoholic fatty liver disease in liver transplant recipients
Zheng-Tao Liu, Tian-Chi Chen, Xiao-Xiao Lu, Hai-Yang Xie, Lin Zhou, Shu-Sen Zheng, Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health and Key Laboratory of Organ Transplantation of Zhejiang Province, Hangzhou 310003, Zhejiang Province, China
Zheng-Tao Liu, Tian-Chi Chen, Xiao-Xiao Lu, Hai-Yang Xie, Lin Zhou, Shu-Sen Zheng, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou 310003, Zhejiang Province, China
Jun Cheng, Shu-Sen Zheng, Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China
Author contributions: Zhou L and Zheng SS designed research; Liu ZT, Chen TC and Lu XX performed research; Xie HY, Zhou L and Zheng SS contributed reagents and analytic tools; Chen TC, Lu XX and Cheng J analyzed data; Liu ZT wrote the paper; and Xie HY, Zhou L and Zheng SS reviewed the paper.
Supported by National S and T Major Project, No. 2012ZX10002017; Foundation for Innovative Research Groups of the National Natural Science Foundation of China, Grant No. 81421062; and China Postdoctoral Science Foundation Project, No. 2015M570518.
Conflict-of-interest statement: Nothing to report.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Shu-Sen Zheng, Professor, Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, 79 QingChun Road, Hangzhou 310003, Zhejiang Province, China. shusenzheng@zju.edu.cn
Telephone: +86-571-87236570 Fax: +86-571-87236570
Received: April 5, 2015
Peer-review started: April 7, 2015
First decision: May 18, 2015
Revised: June 3, 2015
Accepted: July 8, 2015
Article in press: July 8, 2015
Published online: September 14, 2015
Processing time: 162 Days and 11.9 Hours

Abstract

De novo non-alcoholic fatty liver disease (NAFLD) is a common late complication for long-term survivors after liver transplantation. Genomic studies confirmed that PNPLA3 I148M and TM6SF2 E167K polymorphisms affected NAFLD susceptibility in the general population. However, this association was not validated in survivors after liver transplantation (LT). We performed a cross-sectional survey to investigate this relationship. A comprehensive survey, including anthropometric measurements, fasting venous blood sampling, ultrasound, and questionnaires was performed in the short-term. The clinical indications and patient’s steatosis status before LT were collected from inpatient medical records. Sixty-five long-term recipients with a survival exceeding 10 years were enrolled in the final analysis. De novo NAFLD was more frequent in PNPLA3 GG carriers (0.33 vs 0.10 for GG vs CC + CG carriers, P = 0.018), while the genetic impact on NAFLD susceptibility was insignificant when categorized by the TM6SF2 polymorphism (0.19 in CC vs 0.14 in CT + TT carriers, P = 0.883). Multi-covariate analysis revealed that PNPLA3 exerted a significant genetic effect on de novo NAFLD following a recessive model (GG vs CC + CG, OR = 14.2, 95%CI: 1.78-113, P = 0.012). Compared to recipients with only the PNPLA3 GG allele or obesity (defined as body mass index > 25 kg/m2), steatosis was highly prevalent (71.4%) in PNPLA3 GG carriers with obesity. In conclusion, PNPLA3 I148M, but not TM6SF2 E167K, affects de novo NAFLD occurrence with a prominent interaction with obesity. Weight control might be a meaningful method to reduce the genetic susceptibility to NAFLD exerted by PNPLA3 variants.

Key Words: PNPLA3; TM6SF2; Non-alcoholic fatty liver disease; Liver transplantation; Recipient

Core tip: Previous genomic studies identified PNPLA3 I148M and TM6SF2 E167K polymorphisms as the most prominent genetic variations associated with non-alcoholic fatty liver disease (NAFLD) susceptibility in general populations. However, these impacts have never been evaluated in long-term liver transplant recipients. In a collection of survivors 10 years after liver transplantation, we found that the PNPLA3 I148M, but not TM6SF2 E167K polymorphism, affected de novo NAFLD predisposition and interacted with obesity. Our results revealed that liver transplant recipients might benefit from weight control to limit the deleterious effect exerted by genetic factors.



TO THE EDITOR

De novo non-alcoholic fatty liver disease (NAFLD) is a common late complication for long-term survivors after liver transplantation (LT)[1]. De novo NAFLD affects allograft survival indirectly by increasing cardiovascular and infectious disease occurrence[2]. Previous genomic studies identified the PNPLA3 I148M and TM6SF2 E167K polymorphisms as the most likely single nucleotide polymorphisms to influence NAFLD susceptibility in the general population[3]. However, this relationship was not confirmed in long-term survivors after LT as a specific population. Therefore, we performed a cross-sectional survey to investigate the impact of genetic and environmental risk factors for de novo NAFLD in adult long-term survivors after receiving LT.

After obtaining written informed consent, a comprehensive survey, including anthropometric measurements (for body weight and height), fasting venous blood sampling (for liver function, lipid, glucose, viral biomarker testing, genotyping, etc.), ultrasound examination, and questionnaires (for alcohol intake, smoking, exercise, and immunosuppression) were performed over the short-term (December 13th-14th, 2014). Indications for LT and patients’ steatosis status before LT were collected from inpatient medical records. The study was approved by the Institutional Review Board of our hospital.

NAFLD and metabolic syndrome were defined according to previous criteria[4]. Participants with recurrent liver steatosis were excluded. Accordingly, 65 subjects (57 males and 8 females) receiving LT (from September, 1999 to November, 2004) in our hospital with a survival exceeding 10 years were enrolled into the final analysis.

All survivors were Han Chinese and negative for hepatitis B virus DNA/hepatitis C virus RNA assay. As shown in Table 1, twelve of the patients were diagnosed with de novo NAFLD. By univariate analysis, the NAFLD subgroup hada significantly higher body mass index (BMI), triglyceride (TG) levels, and fasting blood glucose (FBG) levels. De novo NAFLD was more frequent in PNPLA3 GG carriers than in CC + CG carriers (0.33 vs 0.10, P = 0.018), while the genetic impact on NAFLD susceptibility was insignificant when categorized by the TM6SF2 polymorphism (0.19 in CC vs 0.14 in CT + TT carriers, P = 0.883). Multi-covariate analysis revealed that PNPLA3 exerted a significant genetic effect on de novo NAFLD following a recessive model (GG vs CC + CG, OR = 14.2, 95%CI: 1.78-113, P = 0.012). Compared to recipients only carrying the PNPLA3 GG allele or being obese (defined as BMI > 25 kg/m2), the prevalence of steatosis was disproportionally higher (71.4%) in PNPLA3 GG carriers who were obese (Figure 1).

Table 1 Current status of long-term recipients surviving more than 10 years.
Univariate
Multivariate
NAFLD (n = 12)Control (n = 53)P valueORP value
Age (yr)56.5 ± 8.453.6 ± 10.10.3561.04 (0.92-1.18)0.528
Gender (M/F)10/247/60.6111.40 (0.14-14.2)0.427
Indication for LT
Hepatitis/cirrhosis/ cancer/others1/8/2/17/35/9/20.889
Survival time (yr)11.2 ± 0.911.5 ± 1.40.541
BMI (kg/m2)25.1 ± 3.022.5 ± 2.60.0031.47 (1.03-2.08)0.032
TG (mmol/L)1.6 ± 1.11.1 ± 0.60.0381.34 (0.38-4.71)0.652
HDL-C (mmol/L)1.2 (1.0-1.4)1.3 (1.0-1.7)0.267
FBG (mmol/L)7.6 ± 3.45.7 ± 1.90.0131.49 (0.93-2.37)0.095
Hypertension (Yes/no)3/921/320.343
SUA (μmol/L)381.6 ± 75.6342.6 ± 76.40.116
MetS (Yes/no)4/89/440.201
ALT (U/L)36.7 ± 7.038.8 ± 6.70.882
Alcohol intake (g/wk)11.6 ± 7.321.0 ± 8.20.766
Smoking (cigar/d)4.2 ± 3.44.3 ± 1.20.969
Exercise (min/d)18.5 ± 6.022.9 ± 2.90.513
Immunosuppression
Tacrolimus/ cyclosporine/ MMF/sirolimus/ none11/1/0/0/036/12/1/2/20.575
PNPLA3 (CC/CG/GG)1/3/816/21/160.01814.2 (1.78-113)0.012
TM6SF2 (CC/CT/TT)11/1/047/5/10.8832.68 (0.25-28.5)0.413
Figure 1
Figure 1 Proportion of the de novo non-alcoholic fatty liver disease/control categorized by the body mass index-PNPLA3 I148M polymorphism. BMI (+) represents BMI ≤ 25 kg/m2; BMI (-) represents BMI > 25 kg/m2; PNPLA3 (+) indicates PNPLA3 I148M GG carriers; PNPLA3 (-) indicates the PNPLA3 I148M CC + CG carriers. BMI: Body mass index; NAFLD: Non-alcoholic fatty liver disease.

This is the first report on the risk factors associated with de novo steatosis in Chinese long-term survivors after LT. PNPLA3, but TM6SF2, affects de novo NAFLD occurrence and has a prominent interaction with obesity. Weight control in recipients might be a potential method to reduce the genetic susceptibility of NAFLD exerted by the PNPLA3 variant.

Footnotes

P- Reviewer: Yu DY S- Editor: Ma YJ L- Editor: A E- Editor: Zhang DN

References
1.  Hübscher SG. What is the long-term outcome of the liver allograft? J Hepatol. 2011;55:702-717.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 101]  [Cited by in F6Publishing: 104]  [Article Influence: 8.0]  [Reference Citation Analysis (0)]
2.  Zezos P, Renner EL. Liver transplantation and non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:15532-15538.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in CrossRef: 118]  [Cited by in F6Publishing: 105]  [Article Influence: 10.5]  [Reference Citation Analysis (0)]
3.  Rinella ME, Sanyal AJ. NAFLD in 2014: Genetics, diagnostics and therapeutic advances in NAFLD. Nat Rev Gastroenterol Hepatol. 2015;12:65-66.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 49]  [Cited by in F6Publishing: 47]  [Article Influence: 5.2]  [Reference Citation Analysis (0)]
4.  Rector RS, Thyfault JP, Wei Y, Ibdah JA. Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol. 2008;14:185-192.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in CrossRef: 213]  [Cited by in F6Publishing: 213]  [Article Influence: 13.3]  [Reference Citation Analysis (0)]